

Top Industry Pharma (TI Pharma)

 consortiapedia.fastercures.org/consortia/ti-pharma/

Research Areas



Tool Development

Resource



Biomarker Research



Basic Research



Product Development

At a Glance

- Status: **Active Consortium**
- Year Launched: **2006**
- Initiating Organization: **Top Industry Pharma**
- Initiator Type: **Nonprofit foundation**
- Location: **International**

Abstract

Top Institute Pharma (TI Pharma) initiates and manages drug development consortia that involve the pharmaceutical industry, academia, and the Dutch government. The aim of all of the consortia is to conduct precompetitive research while strengthening the Netherlands' international reputation for drug development. The focus of all their consortia is on five therapeutic areas: autoimmune diseases, cardiovascular diseases, cancer, infectious diseases, and diseases of the brain.

Mission

TI Pharma was established to initiate and manage drug development consortia to advance the competitiveness of the Netherlands in the pharmaceutical sector, complementing similar Netherlands-based, public-private initiatives to advance diagnostics (Center for Translational Molecular Medicine, CTMM) and devices (BioMedical Materials program, BMM). TI Pharma consortia aim to improve the efficiency of the drug-development process, with a focus on advancing regulatory science. In addition

to research, TI Pharma also has objectives to train and educate scientists in the Netherlands on the drug discovery and development processes, as well as on entrepreneurship.

The consortia are focused on addressing therapeutic areas that are listed as priority areas by the World Health Organization. These include autoimmune diseases, cardiovascular diseases, cancer, infectious diseases, and diseases of the brain. In addition to therapeutic focus, the consortia are also focused on enabling therapeutic target discovery, validation, and animal models; lead selection and in silico modeling; predictive drug disposition and toxicology; biomarkers and biosensors; drug formulation, delivery, and targeting; and production technologies.

Consortium History

2005: Twenty-seven projects selected in first call for proposals

2006: Eighteen projects selected in second call for proposals

Structure & Governance

The TI Pharma strategy is divided into two stages. The first stage, which occurred in 2006, coordinated the Dutch universities and pharmaceutical companies in collaborative research programs (each project is required to have at least three research partners, one of which must represent the industrial or academic community). The second stage started in 2007 with an aim to further increase European involvement via the Seventh Framework Programme, while simultaneously incentivizing participation from U.S.-based pharmaceutical companies.

Participants include all Dutch universities and academic medical centers, more than 30 industrial partners, small-to-medium sized companies, and representatives from the Dutch Medicines Evaluation Board (Netherlands regulatory body for drugs).

Financing

The Dutch government provides €30 million in annual funding, which is matched through financial and in-kind contributions by industry and academia (€15 million, each per year), for four to six years.

Intellectual Property

The TI Pharma consortia follow general principles that govern intellectual property agreements. The principles can be summarized as the following:

Each consortium has one patent coordinator.

Patent Engagement

Several Netherlands patient organizations participate in consortia managed by TI Pharma. These include groups interested in metabolic diseases (VKS: Vereniging Volwassenen, Kinderen en Stofwisselingsziekten), muscle-based diseases (VSN: Vereniging Spierziekten Nederland), and Fabry disease (FSIGN: Fabry Support & Informatie Groep Nederland).

Data Sharing

The level and method of data sharing is dependent on the scientific goals of the consortium.

Impact/Accomplishment

TI Pharma was able to start and manage 96 research consortia within its first six years. Results of the consortia are described in the annual report, which can be found [here](#).

Links/Social Media Feed

Homepage

<http://www.tipharma.com/>

LinkedIn

<https://www.linkedin.com/company/487983>

Points of Contact

TI Pharma
PO Box 142
2300 AC Leiden
The Netherlands
phone: 071-332-2030
fax: 071-332-2031
email: info@tipharma.com

Sponsors & Partners

3D-PharmXchange
Abbott Laboratories
Abbvie/Shire
Academic Medical Center Amsterdam
Actelion
Aeon Astron Europe
Agamyxis
Agendia
Amgen, Inc.
Arcarios
Astellas Pharma Inc.
AstraZeneca
Batavia Bioservices
Bio Detection Systems
Bio Medical Materials Program
Bioceros
Biomade Technology
BioMarin
Bionovion
CardioGenx
Center for Translational Molecular Medicine
Centocor
Centre for Human Drug Research
(Netherlands)

Danone Research
DC Prime
Drugs for Neglected Diseases Initiative
DSM Biomedical
Dutch Polymer Institute
Eli Lilly & Co.
Erasmus University Rotterdam
Fabry Support & Informatie Groep Nederland
Feyecon
Foundation for Innovative New Diagnostics
Galapagos
Galapagos/BioFocus
GE Healthcare
GlaxoSmithKline
Glycostem Therapeutics
Healthcare Insurance Board (Netherlands)
Holst Centre
HQ Medical
Hubrecht Institute
InteRNA Technologies
IOTA Pharmaceuticals
IQ Corporation/IQ Therapeutics
ISA Pharmaceuticals
Isconova
Jan van Es Institute
Johnson & Johnson
KNMP/WINap
Lead Pharma
Leiden University
Life Sciences & Health
Life Sciences & Health cluster organization
LifeAssay Diagnostics
Lundbeck A/S
Maastricht University
Madam Therapeutics
Magistro

Medicines Evaluation Board
Mercachem
Merck Sorono/EMD Serono
Mucosis
Mymetics
Nefarma
Netherlands Cancer Institute
Netherlands Institute for Health Services
Research
Netherlands Institute for Metal Research
Netherlands Institute for Neuroscience
Netherlands Organisation for Applied Scientific
Research (TNO)
Netherlands Vaccine Institute
NOTOX
Nycomed
OctoPlus
PamGene
Pansynt
Pepscan Presto
Percuros
Pfizer, Inc.
Pivot Park Screening Centre
PRA International
Prosensa Therapeutics
PROXY Laboratories
Radboud University Nijmegen
Royal Tropical Institute (KIT)
Sanaria
Sanofi S.A.
Sanofi/Genzyme Corp
Syncom
Synvolux Therapeutics
Telematica Instituut
TropIQ
UbiQ

University Medical Center Groningen
University Medical Center Utrecht
University of Amsterdam
University of Bern
University of Groningen
Utrecht University
Vaxinostics
Vereniging Spierziekten Nederland (VSN)
Vereniging Volwassenen, Kinderen en
Stofwisselingsziekten (VKS)
Vertex Pharmaceuticals Incorporated
ViroClinics
VU University Amsterdam
Wageningen Centre for Food Sciences
Wageningen University and Research Center
Xendo
ZonMW

Updated: **04/08/2016**